STOCK TITAN
  1. Home
  2. News
  3. PDSB

PDS Biotechnology Corporation - $PDSB STOCK NEWS

Welcome to our dedicated page for PDS Biotechnology Corporation news (Ticker: $PDSB), a resource for investors and traders seeking the latest updates and insights on PDS Biotechnology Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PDS Biotechnology Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PDS Biotechnology Corporation's position in the market.

News
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) announced positive results from multiple clinical trials, including a 75% survival rate at 36 months in the NCI-led Phase 2 combination trial for advanced HPV16-positive cancer patients, and a 74% 2-year overall survival rate in the VERSATILE-002 Phase 2 trial for HPV16-positive head and neck cancer patients. The company also reported promising interim safety and immune response data for a Phase 1/2 clinical trial for metastatic prostate cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.55%
Tags
earnings
-
News
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) announced updated survival data from the Phase 2 clinical trial investigating the triple combination of PDS0101, PDS0301, and an investigational immune checkpoint inhibitor (ICI) in advanced cancer patients with HPV16-positive cancers. The trial showed 75% of ICI naïve patients remaining alive at 36 months, with a 12-month survival rate of 72% in ICI resistant patients. PDS0101 plus high doses of ICI and PDS0301 achieved an overall response rate of 63%, while the ORR for PDS0101 plus low doses of ICI and/or PDS0301 was 5%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
clinical trial
-
News
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) will release its financial results for the third quarter of 2023 on November 14, 2023, before the market opens. A conference call will follow to review the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
earnings
News
PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
Rhea-AI Summary
PDS Biotechnology announces immune response data from a Phase 2 clinical trial of PDS0101 in combination with KEYTRUDA in HPV-positive head and neck cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
News
PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
Rhea-AI Summary
PDS Biotech announces positive interim data for Phase 1/2 clinical trial evaluating PDS0301 in combination with docetaxel for metastatic prostate cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
clinical trial
-
News
PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)
Rhea-AI Summary
PDS Biotech announces interim data from VERSATILE-002 trial for head and neck cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.47%
Tags
none
News
PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)
Rhea-AI Summary
PDS Biotech announces data demonstrating rapid decline in HPV circulating cell-free DNA (cfHPV-DNA) with lead candidate PDS0101 in combination with standard-of-care chemoradiotherapy (CRT) in cervical cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
none
-
News
PDS Biotech to Present at the LD Micro Main Event XVI
Rhea-AI Summary
PDS Biotech CEO to present at LD Micro Main Event XVI on October 4, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
conferences
-
News
PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101
Rhea-AI Summary
PDS Biotech reschedules Key Opinion Leader Roundtable on addressing treatments for HPV-positive head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
News
PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Summary
PDS Biotech CEO to participate in panel presentation at Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences
Stock PDSB logo
PDS Biotechnology Corporation

Nasdaq:PDSB

PDSB Rankings

#4038 Ranked by Market Cap
#3526 Ranked by Stock Gains
N/A Ranked by Dividends

PDSB Stock Data

140.11M
35.41M
3.67%
22.93%
16.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PRINCETON

About PDSB

pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati